Can Earnings Grow for Corcept Therapeutics Incorporated (NASDAQ:CORT)?


Corcept Therapeutics Incorporated (NASDAQ:CORT) has a current consensus EPS estimate for the  quarter of $0.01 based on Street analyst predictions. The company is scheduled to next report earnings information on or around 2016-11-03 for the period ending 2016-09-30. In the same quarter last year, the company reported EPS of $0. 

Whether or not the company meets or beats this expectation, along with other factors, can often dictate where the share price might be headed in the near-term. Leading up to the release it’s also important to take note of the direction the estimates are headed as analyst revisions can often give an idea of Street sentiment on expected performance.

Most recently, Corcept Therapeutics Incorporated posted actual earnings of $0.02 per share against the $0.01 Zacks consensus estimate. This represents a surprise factor of 100% or a difference of $0.01. There are currently 4 brokerage firms covering Corcept Therapeutics Incorporated, offering earnings per share estimates as well as future price target projections. On a consensus basis, analysts have pinned a $9.25 mean target price for the short term on the stock. The most lofty price projection sees the stock reaching $12 within the year, while the most conservative has a $5 target on the name.

Zacks provides a simpler approach for understanding analyst recommendations on stocks, using an integer based system which converts each recommendation into a 1-5 average, where 1 represents a Strong Buy and 5 a Strong Sell. Compiling all of the recommendations for the firm, Corcept Therapeutics Incorporated (NASDAQ:CORT) current has a mean recommendation of 1.75.

Analyst recommendations and estimates are for informational purposes only and should be used along with a number of other factors when considering an investment position. 

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Leave a Reply